{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"BET"},{"type":"Synonym","name":"blinatumomab-cultured T cells"},{"type":"Synonym","name":"blinatumomab-expanded peripheral blood-derived T cells"},{"type":"Synonym","name":"blinatumomab-expanded T cells"}],"definition":{"html":"A preparation of autologous, peripheral blood-derived polyclonal activated T cells that have been expanded and activated ex-vivo using blinatumomab and recombinant human IL2 (rhIL-2) and depleted of contaminating CD19+ tumor cells, with potential immunomodulating activity. Upon administration, these blinatumomab-expanded T cells (BET), composed of functional polyclonal CD4+ and CD8+ T cells and mostly effector and central memory cells, may induce immunological recovery. BET cell expansion leads to the lysis and elimination of contaminating CD19+ tumor cells. The elimination of contaminating tumor cells is important in the treatment of non-Hodgkin CD20 + indolent lymphoma (iNHL) and chronic lymphatic leukemia (CLL).","text":"A preparation of autologous, peripheral blood-derived polyclonal activated T cells that have been expanded and activated ex-vivo using blinatumomab and recombinant human IL2 (rhIL-2) and depleted of contaminating CD19+ tumor cells, with potential immunomodulating activity. Upon administration, these blinatumomab-expanded T cells (BET), composed of functional polyclonal CD4+ and CD8+ T cells and mostly effector and central memory cells, may induce immunological recovery. BET cell expansion leads to the lysis and elimination of contaminating CD19+ tumor cells. The elimination of contaminating tumor cells is important in the treatment of non-Hodgkin CD20 + indolent lymphoma (iNHL) and chronic lymphatic leukemia (CLL)."},"drugInfoSummaryLink":null,"nciConceptId":"C170899","nciConceptName":"Autologous Blinatumomab-expanded T-Cells","termId":800850,"name":"autologous blinatumomab-expanded T cells","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"autologous-blinatumomab-expanded-t-cells"},{"aliases":[{"type":"Synonym","name":"anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103"},{"type":"CodeName","name":"MT-103"},{"type":"Synonym","name":"bispecific T-cell engager MT103"},{"type":"CodeName","name":"MEDI-538"},{"type":"USBrandName","name":"Blincyto"},{"type":"CASRegistryName","name":"853426-35-4"},{"type":"CodeName","name":"AMG 103"},{"type":"Synonym","name":"anti-CD19 x anti-CD3 bispecific monoclonal antibody"},{"type":"CodeName","name":"MEDI538"},{"type":"CodeName","name":"MT103"}],"definition":{"html":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B lymphocytes.","text":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B lymphocytes."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/blinatumomab","text":"Blinatumomab"},"nciConceptId":"C62528","nciConceptName":"Blinatumomab","termId":487684,"name":"blinatumomab","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"blinatumomab"}],"links":null}